Valion Bio, Inc.: issues Series B preferred and warrants to 3i, LP for $50,000

What happened

• The filing says Valion Bio, Inc. and 3i, LP are parties to a Securities Purchase Agreement dated Apr 29, 2025 (assigned and amended Dec 9, 2025) covering up to 8,400 Series B Non-Voting Convertible Preferred Shares and related warrants for up to $8,400,000.
• The filing says that on Oct 7, 2026 the company and 3i entered into a letter agreement (the "Third Side Letter") under which 3i agreed to purchase, and the company agreed to issue, 50 Series B Preferred Shares and Series B Warrants to purchase 1,539 shares of common stock at an initial exercise price of $2.5520 per share, for an aggregate purchase price of $50,000, subject to conditions at closing.

Key details

• Letter agreement date: Oct 7, 2026.
• Securities: 50 Series B Non-Voting Convertible Preferred Shares and Series B Warrants to buy 1,539 shares of common stock.
• Price and exercise: aggregate purchase price $50,000; initial exercise price $2.5520 per share.
• Registration status: the filing says the securities were issued under an exemption from registration pursuant to Section 4(a)(2) of the Securities Act and/or Rule 506(b).

Why it may matter

• The filing reports Item 1.01 (entry into a material definitive agreement) and Item 3.02 (unregistered sales of equity securities), which cover the purchase and sale of Series B Preferred Shares and Series B Warrants as described above. A filing does not show why the insider traded or why the company acted.